Y-Biologics
Financials
Valuation Metrics
Y-Biologics's Market Cap is ₩1252B. At end of 2025 it was ₩3527B. Ranked #1141 of 2,421 in KR market (top 47%), #605 of 1,640 on KOSDAQ (top 37%), #131 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 125.23B KRW | KR#1,141/2,421 Sec#131/231 |
| Revenue | 3.17B KRW | KR#2,367/2,421 Sec#204/231 |
| Net Income | -49.95B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 50.19B KRW | KR#2,206/2,421 Sec#199/231 |
| Net Assets | 17.20B KRW | KR#2,323/2,421 Sec#218/231 |
| Employees | 60 | KR#1,965/2,421 Sec#173/231 |
| Value | ||
| P/B | 7.28x | KR#2,313/2,421 Sec#200/231 |
| P/S | 39.50x | KR#2,368/2,421 Sec#195/231 |
| FCF Yield | -5.48% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROA | -99.52% | KR#2,395/2,421 Sec#227/231 |
| Op. Margin | -415.87% | KR#2,361/2,421 Sec#201/231 |
| Revenue Growth | -46.81% | KR#2,280/2,421 Sec#203/231 |
| Financial Health | ||
| Debt Ratio | 191.84% | KR#2,077/2,421 Sec#215/231 |
| Total Debt | 16.10B KRW | KR#1,466/2,421 Sec#122/231 |
| FCF | -6.86B KRW | KR#1,586/2,421 Sec#128/231 |
| Cash | 2.51B KRW | KR#2,198/2,421 Sec#209/231 |
| Current Ratio | 23.81x | KR#17/2,421 Sec#7/231 |
| Performance | ||
| 1Y Return | -40.13% | KR#1,833/2,421 Sec#153/231 |
| 1M Return | -13.42% | KR#2,206/2,421 Sec#187/231 |
| From 52W High | -78.61% | KR#2,330/2,421 Sec#213/231 |
| 1Y MDD | -78.88% | KR#2,278/2,421 Sec#205/231 |
| Trading | ||
| Volume | 18,932 shares | KR#1,614/2,421 Sec#157/231 |
| Trading Value | 154.3M KRW | KR#1,365/2,421 Sec#140/231 |
| Foreign Own. | 6.70% | KR#666/2,421 Sec#58/231 |
| Per Share | ||
| EPS | -3,243 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,116 KRW | KR#2,279/2,421 Sec#206/231 |
Company Info
Y-BIOLOGICS, established in 2007 and listed on KOSDAQ in 2023, focuses on antibody drug research and development. The company leverages its antibody discovery and T-cell bispecific antibody platforms for new drug development, pursuing commercialization through technology transfer and contract research services with global pharmaceutical partners. It has also developed the Multi-AbKine platform for next-generation PD-1 new drugs, employing pH-sensitive antibody mechanism Antibody-Drug Conjugates (ADCs) to specifically target cancer cells.